Search

Displaying results 4981 - 4990 of 5878 in total
  1. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. … It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA).

  2. Drug

    Betaprodine

    go.drugbank.com/drugs/DB01473
    ExperimentalIllicit

    An opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.

  3. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  4. Drug

    Z-Val-Ala-Asp fluoromethyl ketone

    go.drugbank.com/drugs/DB07744
    Experimental

    It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.

  5. Drug

    L-cysteic acid

    go.drugbank.com/drugs/DB03661
    Experimental

    It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.

  6. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).

  7. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608].

  8. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

  9. Drug

    RO7296682

    go.drugbank.com/drugs/DB17531
    Investigational

    RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

    Synonyms: RO 7296682, RO-7296682
  10. Drug

    Lemzoparlimab

    go.drugbank.com/drugs/DB17572
    Investigational

    Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or